Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Conditions Treated With Systemic Immunosuppressive Therapies: A Population-Based Study

ABSTRACT

Incidence proportions of hospitalization, intensive care unit admission, in-hospital death, all-cause mortality, and clinical manifestations of interest were calculated. Baseline Characteristics and IPs of Clinical Manifestations/Outcomes in the RA, PsA, UC, and Comparator Cohorts. a.At least 1 diagnosis of RA, PsA, or UC, and treatment with IM therapy (JAK inhibitor, TNFi, non-TNFi biologic, or csDMARD) within 2 yrs prior to SARS-CoV-2 diagnosis date;b.Absence of a diagnosis of RA, PsA, or UC, and no treatment with IM therapy within 2 yrs prior to SARS-CoV-2 diagnosis date;c.Baseline was defined as within 6 months prior to SARS-CoV-2 diagnosis date;d.csDMARDs included auranofin, aurothioglucose, azathioprine, chloroquine hydrochloride, chloroquine phosphate, cyclophosphamide, cyclosporine, gold sodium thiomalate, hydroxychloroquine sulfate, leflunomide, mercaptopurine, mesalamine, methotrexate, minocycline hydrochloride, n-acetylpenicillamine, penicillamine, primaquine, sulfasalazine, tacrolimus, and thalidomide;e.Within 90 days prior to SARS-CoV-2 diagnosis date;f.Denominator is the number of pts hospitalized within 30 days of SARS-CoV-2 diagnosis;defined as death during hospitalization;g.Within 90 days of SARS-CoV-2 diagnosis date;h.Within 30 days of SARS-CoV-2 diagnosis date. ARDS, acute respiratory distress syndrome;CI, confidence interval;csDMARD, conventional synthetic disease-modifying antirheumatic drug;ECMO, extracorporeal membrane oxygenation;ICU, intensive care unit;IM, immunomodulatory;IP, incidence proportion;IV, intravenous;JAK, Janus kinase;N, number of pts in the cohort;n, number of pts in the specified category;PsA, psoriatic arthritis;pts, patients;RA, rheumatoid arthritis;TNFi, tumor necrosis factor inhibitor;UC, ulcerative colitis.